The amylin field is heat­ing up ahead of No­vo Nordisk’s much-an­tic­i­pat­ed Ca­griSe­ma read­out lat­er this year.

The US Gov­ern­ment Ac­count­abil­i­ty Of­fice pub­lished a new re­port de­tail­ing con­cerns with the staffing of the FDA’s ...

John­son & John­son is su­ing the fed­er­al gov­ern­ment over its re­buke of the com­pa­ny’s al­ter­na­tive mod­el for 340B ...

Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...

Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

Flag­ship Pi­o­neer­ing has ap­point­ed two new CEO-part­ners to ad­vise its port­fo­lio com­pa­nies and help steer its ...

A lot of Am­gen’s fu­ture rides on its ex­per­i­men­tal obe­si­ty med­i­cine Mar­i­Tide. At least in the minds of in­vestors.

Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...